PDL BioPharma Inc

PDL BioPharma — Jefferies 2018 Healthcare Conference

28 slides from PDL BioPharma's conference presentation, Jun 5, 2018

  1. Slide 1: Jefferies 2018 Healthcare Conference

    Slide 1: Jefferies 2018 Healthcare Conference

    PDL Jefferies 2018 Healthcare Conference June 5, 2018 PDL BioPharma, Inc. Nasdaq: PDLI

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements including PDL's expectations with respect to its future royalty revenues, expenses, net income and cash provided by operating activities. Each of these forward-looking statements involves risks and uncertainties. Actual

  3. Slide 3: PDL's Evolving Strategy

    Slide 3: PDL's Evolving Strategy

    PDL’s Evolving Strategy Maximize shareholder value through the acquisition, nurturing and monetization of a portfolio of healthcare companies. Strategic focus on developing and capturing the value of a growing portfolio of operating companies: + Noden Pharma DAC, a specialty pharma company domiciled

  4. Slide 4: Investment Highlights

    Slide 4: Investment Highlights

    Investment Highlights Noden Pharma has built an efficient, global commercial structure for the commercialization of cardiovascular and primary care products: - Generating profitable cash flows with Tekturna® / Rasilez®, leveraging recently stabilized U.S. Rx trends and well-targeted international ma

  5. Slide 5: Business Development and M&A Strategy

    Slide 5: Business Development and M&A Strategy

    Business Development and M&A Strategy Whatwe are looking for: * Commercial-stage products and/or companies whose performance may be improved through access to PDL’s capital and expertise. + Late-stage assets with positive Phase 3 data awaiting regulatory approval. + Biopharma products or companies t

  6. Slide 6: Leadership with Proven Track Record

    Slide 6: Leadership with Proven Track Record

    Leadership with Proven Track Record Executive Management Capabilities & Accomplishments John McLaughlin, CEO * $1 billion in completed transactions Dominique Monnet, President Muitiplesuccesstulll0s * Commercial productlaunches and Geter Cateig CFO. growth in the US and internationally Shriststoners

  7. Slide 7: Noden Pharma

    Slide 7: Noden Pharma

    PDL NODEN y PHARMA

  8. Slide 8: The Noden Transaction

    Slide 8: The Noden Transaction

    The Noden Transaction * Noden Pharma _and Tekturna ®/Rasilez® were PDL’s first operational acquisitions under its new business strategy. * Total Tekturna®/Rasilez® potential purchase price from Novartis is up to $294 million. — $110 million paid at closing in July 2016 and $89 million paid at first

  9. Slide 9: Current Noden Products

    Slide 9: Current Noden Products

    Current Noden Products Tekturna® (U.S.), Rasilez® (ex-U.S.) — contain aliskiren, the first and only approved direct renin inhibitor for the management of hypertension. - Not for use with ACE inhibitors or ARBs in patients with diabetes or renal impairment, pregnant women and pediatric patients below

  10. Slide 10: The Tekturna Opportunity

    Slide 10: The Tekturna Opportunity

    The Tekturna® Opportunity Hypertension is a chronic condition with serious long-term health implications, affecting nearly 50% of all adults in the U.S.1 Angiotensin Converting Enzyme Inhibitors (ACEls) and Angiotensin Il Receptor Blockers (ARBs) are typically first- and second-line therapies. Tektu

  11. Slide 11: Executing on the Commercial Side...

    Slide 11: Executing on the Commercial Side...

    "1 Executing on the Commercial Side... ACE/ ARB Intolerant: SWITCH CCB Notat Goal: ADD Your Patients on Hypertension Monotherapy May Have Uncontroled BP” % Aad as many a5 50% i] D ists Estimated 3.3 million patients Estimated 6 million patients

  12. Slide 12: ...and on the Access Side

    Slide 12: ...and on the Access Side

    12 ...and on the Access Side Source of Tekturna® Business Tekturna® Plan Coverage 42% 53% Commercial Medicare D Jan-18 m= Preferred = Preferred (PA/ST) = Commercial m Medicare All Other = Covered = Covered (PAST) = Cash = All Medicaid = Not Covered Source: IQVIA PlanTrak & Managed Markets Insight &

  13. Slide 13: Stabilizing Tekturna U.S. Prescriptions

    Slide 13: Stabilizing Tekturna U.S. Prescriptions

    Stabilizing Tekturna® U.S. Prescriptions Tekturna Prescription Data - All Strengths (U.S.) Noden resumes promotion with 40 reps Noden field force increased to 60 reps

  14. Slide 14: Maximizing Rasilez Profitability Ex-U.S.

    Slide 14: Maximizing Rasilez Profitability Ex-U.S.

    Maximizing Rasilez® Profitability Ex-U.S. Reviewed each ex-U.S. market and determined to: — Make no investments in direct promotions. — De-register the products in unprofitable markets. - Identify and pursue growth geographies. Actions: - EU: Nov. 2017 assumed commercialization in the EU and Switzer

  15. Slide 15: Tekturna/Rasilez Intellectual Property

    Slide 15: Tekturna/Rasilez Intellectual Property

    Tekturna®/Rasilez® Intellectual Property * United States - Composition-of-matter protection to 2018 for Tekturna®; listed in the Orange Book; — Plus 6-month extension from successful completion of pediatric testing requirements. ~ Composition-of-matter protection until 2022 for Tekturna® HCT. ~ Form

  16. Slide 16: LENSAR: Cataract Laser with Augmented Reality

    Slide 16: LENSAR: Cataract Laser with Augmented Reality

    PDL CATARACT LASER WITH AUGMENTED REALTY

  17. Slide 17: LENSAR

    Slide 17: LENSAR

    7 | LENSAR Converted debt to equity in May 2017. - $119 million in NOLs available. - To consider an exit when shareholder value is maximized. Leading global developer and manufacturer of femtosecond cataract lasers (FLS) for cataract surgery. Cataract surgery is the No. 1 surgical procedure globally

  18. Slide 18: LENSAR Highlights

    Slide 18: LENSAR Highlights

    48 LENSAR Highlights Leading Technology Platform Positioned for Growth >26 million cataract surgeries estimated in 2017. Integrating preop diagnostics is driving growth by delivering better outcomes. Existing treatments are sub-optimal for astigmatism (100% of cataract patients). Widely recognized a

  19. Slide 19: Royalty and Debt Portfolio

    Slide 19: Royalty and Debt Portfolio

    PDL Royalty and Debt Portfolio

  20. Slide 20: Concluded Royalty and Debt Investments

    Slide 20: Concluded Royalty and Debt Investments

    Concluded Royalty and Debt Investments Generated 15.9% IRR Royalty Transaction ‘Senior Secured Financing Wellstat Diagnostics, LUC we $44,000,000 November2012 Royalty Acquisition 3% Depomed 240,500,000 October 2013, ‘Senior Secured Financing A | LENSAR $60,000,000 October 2013, ‘Senior Secured Finan

  21. Slide 21: Cash Flow Funds the New Business Strategy

    Slide 21: Cash Flow Funds the New Business Strategy

    Cash Flow Funds the New Business Strategy: $19.3 million in Q1-2018 indefinite i 6/2018 Bi \ Ome fi 5/2026 p) $240.5M $325.4M > janssen (9/2023 Br | Qi! a, 12/2026 ll J = Payoff $100.0M — $120.0M? “ARIAD ice . 4/2022 $65.6M $9.2M cave: S SANOFI GENZYME ZALVISO” 1/2032 $65.0M $0.2M Sura SE aceD ELEY

  22. Slide 22: Financials

    Slide 22: Financials

    PDL Financials

  23. Slide 23: First Quarter 2018 Income Statement

    Slide 23: First Quarter 2018 Income Statement

    First Quarter 2018 Income Statement Three Months Ended Key Points March 31, (in thousands, except per share amounts) 2018 2017 Royalties from Queen et al. patents S 2,783. _§ 14,156 *Queen et al. patent Royalty rights - change in fair value 11,091 13.146 ‘ Interest revenue 749 5,457 royalties expect

  24. Slide 24: Strong Balance Sheet

    Slide 24: Strong Balance Sheet

    Strong Balance Sheet ($ in millions) Cash, cash equivalents and short-term investments $405 Total Assets $1,100 Debt: 2.75% Convertible Debt — due 12/2021 ($3.81 conversion price)? $150 1) PDLentered into a capped call transaction to offset potential dilution subject to a cap of $4.88. PDL

  25. Slide 25: A History of Value Creation

    Slide 25: A History of Value Creation

    A History of Value Creation Book value per share reached $5.60 as of Mar PDL's Book Value Per Share” a oO SPRPENNNNUWUW ERENT D REASRSASRSASRSASRSasRSas 2 8 3 & & 2°23 a2 2 8 8 8 5 5 & & 8 @ 8 & §€ ¢@ & § @ & € @ @ § € &@ B&B §& § & ¢ 8 8 2 3 &§ 328 86 3 #8 & 8 (1) Does not include asset value of ro

  26. Slide 26: High-Quality Asset Value

    Slide 26: High-Quality Asset Value

    High-Quality Asset Value Assets 1200 Balance 3/31/2018 1000 Selected Component $ millions Per Share 800 Royalty Rights $ 3417 $ 227 Noden & LensarBook Value $ 213.2 $ 142 600 Notes Receivable $70.7 $0.47 Total Investments $ 625.6 $ 4.16 400 EE Cosh $405.1 $2.69 200 Debt $ (150.0) $ (1.00) Net Cash $

  27. Slide 27: Share Repurchase Program

    Slide 27: Share Repurchase Program

    Share Repurchase Program « While our focus is on the strategic acquisition of biopharma assets, given the significant discount of PDL’s stock price to its book value, we have implemented share repurchase programs to return value to shareholders. ¢ Current Program — $25 Million - In September 2017 PD

  28. Slide 28: Why Invest in PDLI?

    Slide 28: Why Invest in PDLI?

    Why Invest in PDLI? Upside from the new business model

Source: SEC EDGAR · 8-K filed Jun 5, 2018

More decks from PDL BioPharma Inc